1. Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma Arch Ophthalmol. 2012;130(4):497-505. doi:10.1001/archophthalmol.2011.2727 Figure 1. Markov model. OAG indicates open-angle glaucoma. Figure Legend:

2. Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma Arch Ophthalmol. 2012;130(4):497-505. doi:10.1001/archophthalmol.2011.2727 Figure 2. Markov tracings of glaucoma severity over time for the untreated cohort (A), the cohort treated with prostaglandin analogs (B), and the cohort treated with laser trabeculoplasty (C). Figure Legend:

3. Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma Arch Ophthalmol. 2012;130(4):497-505. doi:10.1001/archophthalmol.2011.2727 Figure 3. Cost-effectiveness plane comparing the effectiveness of glaucoma medications, laser trabeculoplasty, and no treatment. Figure Legend:

4. Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma Arch Ophthalmol. 2012;130(4):497-505. doi:10.1001/archophthalmol.2011.2727 Figure 4. Two-way sensitivity analysis simultaneously varying the effectiveness of prostaglandin analogs and laser trabeculoplasty in a base model. Each axis captures the relative effectiveness of each intervention at delaying glaucoma progression. A value of 1.0 means the base case effectiveness as outlined in the article; higher values represent greater effectiveness and lower values represent reduced effectiveness (eg, a value of 0.75 means a 25% reduction in effectiveness). Each region represents the preferred intervention, assuming a willingness to pay $100 000 per quality-adjusted life year. Figure Legend: